⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7322261 | 0.79 | FDPS (0.33) | — | |
| SCHEMBL1231923 | 0.78 | — | — | |
| SCHEMBL12888007 | 0.76 | — | — | |
| SCHEMBL2734111 | 0.70 | — | — | |
| SCHEMBL62598 | 0.67 | — | — | |
| SCHEMBL21911602 | 0.65 | — | — | |
| SCHEMBL23789498 | 0.63 | — | — | |
| SCHEMBL18027537 | 0.61 | — | — | |
| SCHEMBL10308723 | 0.61 | TSHR (0.32) | — | |
| SCHEMBL6379610 | 0.61 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245009-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-20150246881-A1 | Processes | NOVARTIS AG (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9061973-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8716481-B2 | Process for the preparation of 6-substituted-1-(2H)-isoquinolinones | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2245009-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090251-A2 | NEW PROCESSES | NOVARTIS AG (CH) | 2009-07-23 | — | — | WO | disclosed |
| US-4716170-A | 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use | STERLING DRUG INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4697021-A | 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-09-29 | — | — | US | disclosed |
| US-4657915-A | INOTROPIC AGENTS | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4634772-A | 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0189853-A2 | 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation | STERLING DRUG INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| EP-0009554-A1 | Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-04-16 | — | — | EP | disclosed |